This trial is testing if cemiplimab monotherapy is better than cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC.
2 Primary · 14 Secondary · Reporting Duration: up to 5 years
Active Control
Experimental Treatment
180 Total Participants · 2 Treatment Groups
Primary Treatment: RP1 · No Placebo Group · Phase 2
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: